» Articles » PMID: 37581056

Topological Properties of Individual Gray Matter Morphological Networks in Identifying the Preclinical Stages of Alzheimer's Disease: a Preliminary Study

Overview
Specialty Radiology
Date 2023 Aug 15
PMID 37581056
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Subjective cognitive decline (SCD) and mild cognitive impairment (MCI) are preclinical stages of Alzheimer's disease (AD). Individual biomarkers are essential for evaluating altered neurological outcomes at both SCD and MCI stages for early diagnosis and intervention of AD. In this study, we aimed to investigate the relationships between topological properties of the individual brain morphological network and clinical cognitive performances among healthy controls (HCs) and patients with SCD or MCI.

Methods: The topological measurements of individual morphological networks were analyzed using graph theory, and inter-group differences of standard graph topology were correlated and regressed to scores of clinical cognitive functions.

Results: Compared with HCs, the topology of the individual morphological networks in SCD and MCI patients was significantly altered. At the global level, altered topology was characterized by lower global efficiency, shorter characteristics path length, and normalized characteristics path length [all P<0.05, false discovery rate (FDR) corrected]. In addition, at the regional level, SCD and MCI patients exhibited abnormal degree centrality in the caudate nucleus and nodal efficiency in the caudate nucleus, right insula, lenticular nucleus, and putamen (all P<0.05, FDR corrected).

Conclusions: The topological features of individual gray matter morphological networks may serve as biomarkers to improve disease prognosis and intervention in the early stages of AD, namely SCD and MCI. Moreover, these findings may further elucidate the relationships between brain morphological alterations and cognitive dysfunctions in SCD and MCI.

Citing Articles

Research progress on brain network imaging biomarkers of subjective cognitive decline.

Yingmei H, Chaojie W, Yi Z, Yijie L, Heng Z, Ze F Front Neurosci. 2025; 19:1503955.

PMID: 40018359 PMC: 11865231. DOI: 10.3389/fnins.2025.1503955.


Differences of individual gray matter networks between MCI patients who converted to AD within 3 Years and nonconverters.

Zhou B, Zhao Y, Wu X Heliyon. 2024; 10(7):e28874.

PMID: 38623255 PMC: 11016615. DOI: 10.1016/j.heliyon.2024.e28874.

References
1.
Jessen F, Amariglio R, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G . A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014; 10(6):844-52. PMC: 4317324. DOI: 10.1016/j.jalz.2014.01.001. View

2.
Yu K, Wang X, Li Q, Zhang X, Li X, Li S . Individual Morphological Brain Network Construction Based on Multivariate Euclidean Distances Between Brain Regions. Front Hum Neurosci. 2018; 12:204. PMC: 5981802. DOI: 10.3389/fnhum.2018.00204. View

3.
Levitt J, McCarley R, Dickey C, Voglmaier M, Niznikiewicz M, Seidman L . MRI study of caudate nucleus volume and its cognitive correlates in neuroleptic-naive patients with schizotypal personality disorder. Am J Psychiatry. 2002; 159(7):1190-7. PMC: 2826363. DOI: 10.1176/appi.ajp.159.7.1190. View

4.
Berlot R, Metzler-Baddeley C, Ikram M, Jones D, OSullivan M . Global Efficiency of Structural Networks Mediates Cognitive Control in Mild Cognitive Impairment. Front Aging Neurosci. 2016; 8:292. PMC: 5157053. DOI: 10.3389/fnagi.2016.00292. View

5.
Cummings J, Morstorf T, Zhong K . Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014; 6(4):37. PMC: 4095696. DOI: 10.1186/alzrt269. View